Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 10fludarabine phosphate 9Rituximab 9Cytarabine 9Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Filgrastim 6Cyclosporine 6fludarabine 5Radiotherapy 5Busulfan 5Tacrolimus 4Mycophenolic Acid 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4Bendamustine Hydrochloride 4venetoclax 3duvelisib 3Whole-Body Irradiation 3Sirolimus 3Melphalan 3Antilymphocyte Serum 3Prednisone 2N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 2Mitoxantrone 2Lenalidomide 2Interferon-alpha 2Drug Therapy 2Clofarabine 2Arsenic Trioxide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia × fedratinib × Clear all
NCT04955938 2024-07-31

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

University of Chicago

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡